Susceptibility of ceftolozane/tazobactam against multidrug-resistant and carbapenem-resistant Pseudomonas aeruginosa. 2023

Ayaka Kakehi, and Hideharu Hagiya, and Koji Iio, and Takumi Fujimori, and Mami Okura, and Hiroshi Minabe, and Yukika Yokoyama, and Fumio Otsuka, and Akihito Higashikage
Microbiology Division, Clinical Laboratory, Okayama University Hospital, Okayama, Japan.

Ceftolozane (CTLZ) is a novel cephalosporin antibiotic that exhibits broad-spectrum activity against gram-negative pathogens, including Pseudomonas aeruginosa, especially when combined with tazobactam (TAZ). We examined the minimum inhibitory concentration (MIC) of CTLZ/TAZ for 21 multidrug-resistant P. aeruginosa (MDRP) and eight carbapenem-resistant P. aeruginosa (CRPA) strains isolated at Okayama University Hospital, Japan. Consequently, 81% (17/21) of the MDRP strains and 25% (2/8) of the CRPA strains were resistant to CTLZ/TAZ (MIC >8 μg/mL). All 18 blaIMP-positive strains showed resistance to CTLZ/TAZ, whereas the drug retained in vitro susceptibility in 54.5% (6/11 strains) of blaIMP-negative strains.

UI MeSH Term Description Entries
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D010397 Penicillanic Acid A building block of penicillin, devoid of significant antibacterial activity. (From Merck Index, 11th ed) Acid, Penicillanic
D011550 Pseudomonas aeruginosa A species of gram-negative, aerobic, rod-shaped bacteria commonly isolated from clinical specimens (wound, burn, and urinary tract infections). It is also found widely distributed in soil and water. P. aeruginosa is a major agent of nosocomial infection. Bacillus aeruginosus,Bacillus pyocyaneus,Bacterium aeruginosum,Bacterium pyocyaneum,Micrococcus pyocyaneus,Pseudomonas polycolor,Pseudomonas pyocyanea
D011552 Pseudomonas Infections Infections with bacteria of the genus PSEUDOMONAS. Infections, Pseudomonas,Pseudomonas aeruginosa Infection,Infection, Pseudomonas,Pseudomonas Infection,Pseudomonas aeruginosa Infections
D002511 Cephalosporins A group of broad-spectrum antibiotics first isolated from the Mediterranean fungus ACREMONIUM. They contain the beta-lactam moiety thia-azabicyclo-octenecarboxylic acid also called 7-aminocephalosporanic acid. Antibiotics, Cephalosporin,Cephalosporanic Acid,Cephalosporin,Cephalosporin Antibiotic,Cephalosporanic Acids,Acid, Cephalosporanic,Acids, Cephalosporanic,Antibiotic, Cephalosporin,Cephalosporin Antibiotics
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000078142 Tazobactam A penicillanic acid and sulfone derivative and potent BETA-LACTAMASE inhibitor that enhances the activity of other anti-bacterial agents against beta-lactamase producing bacteria. Tazobactam Sodium,YTR 830,YTR 830H,YTR-830,YTR830
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D015780 Carbapenems A group of beta-lactam antibiotics in which the sulfur atom in the thiazolidine ring of the penicillin molecule is replaced by a carbon atom. THIENAMYCINS are a subgroup of carbapenems which have a sulfur atom as the first constituent of the side chain. Antibiotics, Carbapenem,Carbapenem,Carbapenem Antibiotics
D024901 Drug Resistance, Multiple, Bacterial The ability of bacteria to resist or to become tolerant to several structurally and functionally distinct drugs simultaneously. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Drug Resistance, Extensive, Bacterial,Drug Resistance, Extensively, Bacterial,Extensive Antibacterial Drug Resistance,Extensively Antibacterial Drug Resistance,Multidrug Resistance, Bacterial,Multiple Antibacterial Drug Resistance,Bacterial Multidrug Resistance,Bacterial Multidrug Resistances,Resistance, Bacterial Multidrug

Related Publications

Ayaka Kakehi, and Hideharu Hagiya, and Koji Iio, and Takumi Fujimori, and Mami Okura, and Hiroshi Minabe, and Yukika Yokoyama, and Fumio Otsuka, and Akihito Higashikage
October 2019, Revista chilena de infectologia : organo oficial de la Sociedad Chilena de Infectologia,
Ayaka Kakehi, and Hideharu Hagiya, and Koji Iio, and Takumi Fujimori, and Mami Okura, and Hiroshi Minabe, and Yukika Yokoyama, and Fumio Otsuka, and Akihito Higashikage
August 2023, Pathology,
Ayaka Kakehi, and Hideharu Hagiya, and Koji Iio, and Takumi Fujimori, and Mami Okura, and Hiroshi Minabe, and Yukika Yokoyama, and Fumio Otsuka, and Akihito Higashikage
December 2023, Enfermedades infecciosas y microbiologia clinica (English ed.),
Ayaka Kakehi, and Hideharu Hagiya, and Koji Iio, and Takumi Fujimori, and Mami Okura, and Hiroshi Minabe, and Yukika Yokoyama, and Fumio Otsuka, and Akihito Higashikage
February 2018, Journal of clinical microbiology,
Ayaka Kakehi, and Hideharu Hagiya, and Koji Iio, and Takumi Fujimori, and Mami Okura, and Hiroshi Minabe, and Yukika Yokoyama, and Fumio Otsuka, and Akihito Higashikage
January 2022, Antimicrobial agents and chemotherapy,
Ayaka Kakehi, and Hideharu Hagiya, and Koji Iio, and Takumi Fujimori, and Mami Okura, and Hiroshi Minabe, and Yukika Yokoyama, and Fumio Otsuka, and Akihito Higashikage
March 2020, Acta microbiologica et immunologica Hungarica,
Ayaka Kakehi, and Hideharu Hagiya, and Koji Iio, and Takumi Fujimori, and Mami Okura, and Hiroshi Minabe, and Yukika Yokoyama, and Fumio Otsuka, and Akihito Higashikage
May 2020, The Pediatric infectious disease journal,
Ayaka Kakehi, and Hideharu Hagiya, and Koji Iio, and Takumi Fujimori, and Mami Okura, and Hiroshi Minabe, and Yukika Yokoyama, and Fumio Otsuka, and Akihito Higashikage
May 2021, Antimicrobial agents and chemotherapy,
Ayaka Kakehi, and Hideharu Hagiya, and Koji Iio, and Takumi Fujimori, and Mami Okura, and Hiroshi Minabe, and Yukika Yokoyama, and Fumio Otsuka, and Akihito Higashikage
January 2022, Diagnostic microbiology and infectious disease,
Ayaka Kakehi, and Hideharu Hagiya, and Koji Iio, and Takumi Fujimori, and Mami Okura, and Hiroshi Minabe, and Yukika Yokoyama, and Fumio Otsuka, and Akihito Higashikage
March 2017, Antimicrobial agents and chemotherapy,
Copied contents to your clipboard!